Efficacy of ALK5 inhibition in myelofibrosis.

Myelofibrosis (MF) is a bone marrow disorder characterized by clonal myeloproliferation, aberrant cytokine production, extramedullary hematopoiesis, and bone marrow fibrosis. Although somatic mutations in JAK2, MPL, and CALR have been identified in the pathogenesis of these diseases, inhibitors of the Jak2 pathway have not demonstrated efficacy in ameliorating MF in patients. TGF-beta family members are profibrotic cytokines and we observed significant TGF-beta 1 isoform overexpression in a large cohort of primary MF patient samples. Significant overexpression of TGF-beta 1 was also observed in murine clonal MPLW515L megakaryocytic cells. TGF-beta 1 stimulated the deposition of excessive collagen by mesenchymal stromal cells (MSCs) by activating the TGF-beta receptor I kinase (ALK5)/Smad3 pathway. MSCs derived from MPLW515L mice demonstrated sustained overproduction of both collagen I and collagen III, effects that were abrogated by ALK5 inhibition in vitro and in vivo. Importantly, use of galunisertib, a clinically active ALK5 inhibitor, significantly improved MF in both MPLW515L and JAK2(V617F) mouse models. These data demonstrate the role of malignant hematopoietic stem cell (HSC)/TGF-beta/MSC axis in the pathogenesis of MF, and provide a preclinical rationale for ALK5 blockade as a therapeutic strategy in MF.